By Fineline Cube 
German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to assess the safety, tolerability, and preliminary efficacy of 225Ac-GPC3 (BAY 3547926) in patients with advanced hepatocellular carcinoma (HCC). The study will evaluate the drug both as a monotherapy and in combination with other treatments.
BAY 3547926: Mechanism of Action
BAY 3547926 is an investigational targeted alpha radiopharmaceutical designed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced HCC. The drug is composed of a high-affinity antibody targeting GPC3, radiolabeled with actinium-225 (225Ac). This targeted approach delivers highly potent alpha-particles directly to GPC3-expressing cancer cells, with the potential to induce DNA double-strand breaks. This mechanism reduces cancer cell viability and may lead to significant anti-tumor activity.-Fineline Info & Tech